| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7958f7df39e0db38df697cf6cba262f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C53-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-664
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-6561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65616
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C57-15 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C53-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-664
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-6524
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C57-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65616 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C53-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C57-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-664 |
| filingDate |
2017-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dcc23a78fc1346641c7ae78680777fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ab2f0e392e2be0b6de317a1e94cd654 |
| publicationDate |
2019-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
MX-2019010200-A |
| titleOfInvention |
(S) -2 - [[[(R) -2- (6-AMINOPURIN-9-IL) -1-METHYL-ETHOXY] METHYL-PHENOXY-FOS FORYL] AMINO] -CYCLOBUTYL PROPANOATES AND PRODUCTION AND APPLICATION PROCESS THEREOF. |
| abstract |
The present invention relates to chemotherapeutic agents for the treatment of viral and cancerous diseases; These compounds are prodrugs of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) DNA polymerase inhibitors and are intended for the treatment of human immunodeficiency virus, hepatitis B and HIV / HCV co-infections. , HIV / HBV, HIV / HCV / HBV and HCV / HBV. |
| priorityDate |
2017-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |